The GLP-1 Cardiovascular Data: LEADER, SUSTAIN-6, SELECT — What Practitioners Should Know

The GLP-1 Cardiovascular Data: LEADER, SUSTAIN-6, SELECT — What Practitioners Should Know

Cardiovascular outcomes associated with GLP-1 receptor agonists have gained significant attention following the results of major trials: LEADER, SUSTAIN-6, and SELECT. Understanding these studies is crucial for practitioners, especially as the implications for off-label prescribing expand.

LEADER Trial Overview

The LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) was a pivotal randomized controlled trial (RCT) that evaluated the cardiovascular safety of liraglutide in patients with type 2 diabetes at high cardiovascular risk. Published in 2016, LEADER demonstrated a significant reduction in major adverse cardiovascular events (MACE), defined as a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, by 13% compared to placebo (N Engl J Med. 2016; 375:311-322). The trial included over 9,000 participants and provided robust evidence supporting the cardiovascular benefits of liraglutide.

SUSTAIN-6 Trial Insights

Following LEADER, the SUSTAIN-6 trial (Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes) further solidified the role of GLP-1 receptor agonists in cardiovascular risk management. Published in 2016, SUSTAIN-6 demonstrated that semaglutide, another GLP-1 receptor agonist, reduced MACE by 26% compared to placebo (N Engl J Med. 2016; 375:1834-1844). This trial included 3,297 participants and was notable for its inclusion of patients with a history of cardiovascular disease as well as those at high risk.

SELECT Trial: A Paradigm Shift

The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People Without Diabetes) represents a significant evolution in the understanding of GLP-1 receptor agonists. Conducted to evaluate the cardiovascular effects of semaglutide in non-diabetic patients with cardiovascular risk factors, SELECT was published in 2023 and revealed a remarkable 20% reduction in MACE among participants receiving semaglutide compared to placebo (N Engl J Med. 2023; 388: 124-135). This trial included a diverse population of over 17,000 participants and is particularly noteworthy because it extends the cardiovascular benefits of GLP-1 receptor agonists beyond the diabetic population.

Implications for Off-Label Prescribing

The findings from SELECT are particularly relevant for practitioners considering off-label use of GLP-1 receptor agonists for cardiovascular risk reduction in non-diabetic patients. While LEADER and SUSTAIN-6 established the cardiovascular safety and benefits of these agents in diabetic populations, SELECT provides evidence that these benefits can also apply to individuals without diabetes who are at risk for cardiovascular events.

However, it is essential to approach off-label prescribing with caution. The data from SELECT, while compelling, is still emerging. The FDA has not yet approved semaglutide for cardiovascular risk reduction in non-diabetic patients, and practitioners should weigh the potential benefits against the lack of long-term safety data in this population.

Key Differences Between Trials

The primary distinction between SELECT and its predecessors lies in the patient population. LEADER and SUSTAIN-6 focused on individuals with type 2 diabetes, while SELECT targeted non-diabetic individuals with cardiovascular risk factors. This shift in focus underscores a broader application of GLP-1 receptor agonists and suggests a potential new role in primary prevention strategies.

Furthermore, the magnitude of risk reduction observed in SELECT (20%) is comparable to that seen in LEADER (13%) and SUSTAIN-6 (26%), indicating that GLP-1 receptor agonists may offer substantial cardiovascular benefits across different patient populations.

Conclusion

The cardiovascular data from LEADER, SUSTAIN-6, and SELECT highlight the evolving landscape of GLP-1 receptor agonists in cardiovascular risk management. SELECT, in particular, marks a significant advancement by demonstrating cardiovascular benefits in non-diabetic patients, paving the way for potential off-label use. However, practitioners must remain vigilant about the lack of FDA approval for this indication and the need for further long-term studies to ensure safety